Artemisia extracts activate PPARγ, promote adipogenesis, and enhance insulin sensitivity in adipose tissue of obese mice

Allison J. Richard  
*Pennington Biomedical Research Center*

Thomas P. Burris  
*Scripps Florida*

David Sanchez-Infantes  
*Endocrinology Department*

Yongjun Wang  
*Scripps Florida*

David M. Ribnicky  
*Rutgers University–New Brunswick*

*See next page for additional authors*

Follow this and additional works at: https://repository.lsu.edu/biosci_pubs

**Recommended Citation**


This Article is brought to you for free and open access by the Department of Biological Sciences at LSU Scholarly Repository. It has been accepted for inclusion in Faculty Publications by an authorized administrator of LSU Scholarly Repository. For more information, please contact ir@lsu.edu.
Artemisia extracts activate PPARγ, promote adipogenesis, and enhance insulin sensitivity in adipose tissue of obese mice

Allison J. Richard¹, Thomas P. Burris², David Sanchez-Infantes³, Yongjun Wang², David M. Ribnicky⁴, and Jacqueline M. Stephens¹,*

¹Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, LA 70808
²The Scripps Research Institute Jupiter, FL 33458
³Endocrinology Department, Saint Joan de Deu, Barcelona, Spain
⁴Biotech Center, Rutgers University, New Brunswick, NJ 08901

Abstract

Objective—Studies have shown that the inability of adipose tissue to properly expand during the obese state or respond to insulin can lead to metabolic dysfunction. Artemisia is a diverse group of plants that has a history of medicinal use. This study examines the ability of ethanolic extracts of Artemisia scoparia (SCO) and Artemisia santolinifolia (SAN) to modulate adipocyte development in cultured adipocytes and white adipose tissue (WAT) function in vivo using a mouse model of diet-induced obesity.

Research Design & Procedures—Adipogenesis was assessed using Oil Red O staining and immunoblotting. A nuclear receptor specificity assay was used to examine the specificity of SCO- and SAN-induced PPARγ activation. C57BL/6J mice, fed a high-fat diet, were gavaged with saline, SCO, or SAN for 2 weeks. Whole-body insulin sensitivity was examined using insulin tolerance tests. WAT depots were assessed via immunoblotting for markers of insulin action and adipokine production.

Results—We established that SCO and SAN were highly specific activators of PPARγ and did not activate other nuclear receptors. After a one-week daily gavage, SCO- and SAN-treated mice had lower insulin-induced glucose disposal rates than control mice. At the end of the 2-week treatment period, SCO- and SAN-treated mice had enhanced insulin-responsive Akt serine-473 phosphorylation and significantly decreased MCP-1 levels in visceral WAT relative to control
mice; these differences were depot specific. Moreover, plasma adiponectin levels were increased following SCO treatment.

**Conclusion**—Overall, these studies demonstrate that extracts from two *Artemisia* species can have metabolically favorable effects on adipocytes and WAT.

**Keywords**

fat cells; insulin action; botanicals; Diet Induced Obesity; 3T3-L1 adipocytes

---

**Introduction**

Adipocytes are dynamic insulin-sensitive cells that have endocrine properties and contribute to whole body energy homeostasis. Obesity is the primary disease of fat cells and significantly contributes to the development of type 2 diabetes mellitus (T2DM), cardiovascular disease, and certain cancers. Many researchers have investigated anti-adipogenic agents, including some botanicals, as potential therapeutics for decreasing or preventing obesity. However, the prevailing current hypothesis is that disruption of adipocyte differentiation limits adipose tissue expansion and leads to insulin resistance and the development of T2DM [1–4].

Botanical extracts represent an alternative approach for the treatment or prevention of a disease. Plant extracts are used by many cultures and have resulted in the development of many drugs, including metformin. Metformin is a widely used T2DM drug that is derived from French lilac. In a blinded screening study to investigate the effects of botanicals on adipocyte differentiation, we identified plant extracts with substantial effects on adipogenesis. Two of these extracts were *Artemisia* species, *Artemisia scoparia* (SCO) and *Artemisia santolinifolia* (SAN). Many *Artemisia* species have been used in traditional medicine in East Asia, and are reported to demonstrate anti-hyperglycemic [5, 6], anti-obesity [7, 8], and anti-diabetic activities [5, 9]. Our studies revealed that both SCO and SAN could promote adipocyte development in differentiating murine adipocytes. In addition, these extracts specifically activate PPARγ, but did not modulate the activity of other nuclear receptors. We also observed that SCO and SAN could increase adiponectin (ADPN) secretion *in vitro* and *in vivo*. In a 2-week gavage study, SCO and SAN enhanced insulin action in epididymal adipose tissue. These studies demonstrate that SCO and SAN have a positive impact on adipocyte-related diseases by promoting adipocyte development and increasing adiponectin levels and insulin action in adipose tissue.

**Materials and Methods**

**Chemicals and reagents**

Dulbecco’s modified Eagle’s medium (DMEM) was purchased from Sigma-Aldrich (St. Louis, MO). Bovine and fetal bovine sera were purchased from HyClone (Thermo Scientific, Logan, UT). For immunoblotting, STAT5A, MAPK/ERK, and PPARγ antibodies were purchased from Santa Cruz Biototechnology (Santa Cruz, CA). The anti-adiponectin antibody was obtained from Thermo Scientific (Rockford, IL). Anti-phospho-Akt-Ser473 (Aktp(S(473)), total Akt, and monocyte chemotactic protein-1 (MCP-1) antibodies...
were purchased from Cell Signaling Technology, Inc. (Danvers, MA). With the exception of the mouse monoclonal anti-PPARγ IgG, all other antibodies were rabbit polyclonal IgGs, and peroxidase-conjugated secondary antibodies to both species were purchased from Jackson ImmunoResearch (West Grove, PA). The BCA and enhanced chemiluminescence kits were from Thermo Scientific.

**Preparation, source and characterization of the extracts**

*Artemisia scoparia* Waldst. & Kit and *Artemisia santolinifolia* Turcz. ex Besser ethanolic extracts were prepared at Rutgers University. Briefly, the herb was greenhouse grown from seed and periodically harvested at the flowering stage, freeze dried and stored at −20°C. The dried herb was extracted in 80% ethanol (1:20 w/v), at 50°C with sonication for 1 hour followed by shaking at room temperature for 24 h. The solid material was removed by centrifugation at 3000 g and the solvent was subsequently removed by evaporation. For *in vitro* and cell culture experiments, the dried extracts were solubilized in 100% DMSO at a concentration that was 1000-fold higher than experimental concentrations and then diluted into the media. For animal studies, the extracts were solubilized in 20% Labrasol® (Gattefosse, Lyon, France) and administered via gavage.

**Nuclear receptor specificity assay**

SCO and SAN were assessed for their ability to modulate the activities of all 48 human nuclear receptors using a previously described Gal4 co-transfection assay system [10–12]. Both extracts were tested at 50 µg/ml and positive controls were included for characterized ligands. DMSO was used as the vehicle control.

**Cell culture**

Murine 3T3-L1 preadipocytes were plated and grown to 2 days post-confluence in DMEM containing 10% bovine serum. Medium was changed every 48–72 hours. Cells were induced to differentiate using a standard MDI induction protocol [13]. Mature adipocytes were maintained in DMEM supplemented with 10% FBS until utilized for experimentation. For adipogenesis assays, the botanical extracts were added at the time of MDI induction and at each media change until the cells were stained with Oil Red O (ORO) or harvested for western blot analysis.

**Oil Red O staining**

An ORO stock was prepared as previously described [14]. Cell monolayers were aspirated, rinsed with PBS, fixed in 10% formaldehyde/PBS, and rinsed under tap water. The remaining water was aspirated, and the cells were incubated for 1 h in the working ORO solution (0.3% in isopropanol). Following incubation, stain aspiration, and rinsing, cells were examined by microscopy and scanned to produce the figures in this manuscript.

**Animals and gavage**

Thirty-six 16-week old male C57BL/6J-diet-induced obese (DIO) mice were purchased from Jackson Laboratories (Bar Harbor, ME) and maintained on a purified high-fat diet (HFD) containing 20 kcal% protein, 20 kcal% carbohydrate, and 60 kcal% fat (D12492;
Research Diets, Inc., New Brunswick, NJ) for the entire study. After one week in quarantine, mice were housed four per cage in a temperature- and humidity-controlled room with a 12-hour light/dark cycle. Mice were handled daily for 2 weeks and non-fasting body weights were recorded daily. Non-fasting NMR (Brukner Minispec) was recorded on day 14. Animals were gavaged (22 gauge plastic gavage needle, Instech Laboratories, Inc. Plymouth Meeting, PA) with 20% Labrasol® daily for 7 days. On day 21, another non-fasting NMR measurement was recorded and submandibular blood samples were collected. Animals were randomized by non-fasting body weight (day 21) to one of 3 groups: 20% Labrasol® (CTL; n=12), SCO (n=12), and SAN (n=12) and gavaged daily for an additional 2 weeks. Botanical extracts were prepared in 20% Labrasol® to increase bioavailability. All animal studies were performed with approval from the Pennington Biomedical Research Center Institutional Animal Care and Use Committee.

Animal Study Procedures

Non-fasted body weight was measured daily during the 2-week gavage study. Body composition (NMR), fasting body weight, fasting plasma glucose, insulin, and adiponectin levels were measured at the beginning (baseline measurements) and end of the 2-week study period. One week following the initiation of experimental gavaging, and 4 hours after mice received their last gavage, intraperitoneal insulin tolerance tests (IPITTs) were performed on all animals. Briefly, a baseline blood glucose measurement was obtained via tail nick (0 minutes), and animals were then injected with 1U/kg insulin (Humulin R, Eli Lilly, Indianapolis, IN). Blood glucose measurements were obtained via tail nick at 10, 20, 40, and 60 minutes post-injection. All blood glucose measurements were performed using a Bayer Breeze 2 glucometer. Following 2 weeks of experimental gavage, mice were fasted overnight and a fasted body weight, submandibular blood collection, and NMR measurement were obtained for each mouse. Immediately following these procedures, mice were gavaged with the appropriate extract or vehicle. Four hours after the gavage, mice were injected with either 1 U/kg insulin or saline and euthanized via cervical dislocation 10–15 minutes after injections. Animals were then decapitated and trunk blood collected. Retroperitoneal white adipose tissue (rWAT), inguinal adipose tissue (iWAT), and epididymal adipose tissue (eWAT) depots were collected and immediately frozen in liquid nitrogen.

Whole cell extract and tissue preparation

Adipocyte whole cell extracts and WAT lysates were prepared by either harvesting adipocyte monolayers or homogenizing WAT in a non-denaturing extraction buffer containing 150 mM NaCl, 10 mM Tris, pH 7.4, 1 mM EGTA, 1 mM EDTA, 1% Triton X-100, 0.5% Igepal CA-630, 1 mM phenylmethylsulfonyl fluoride, 1 µM pepstatin, 50 trypsin inhibitory milliunits of aprotinin, 10 µM leupeptin, 1mM 1, 10-phenanthroline, and 0.2 mM sodium vanadate. Protein content was determined by BCA protein assay (Bio-Rad laboratories, Inc., Hercules, CA).

Gel electrophoresis and immunoblotting

Samples were separated on 7.5, 10, or 15% SDS-polyacrylamide gels (PA) and transferred to nitrocellulose membranes. Results were visualized with horseradish peroxidase-
conjugated secondary antibodies and enhanced chemiluminescence. For native gel electrophoresis, 5% PA gels were prepared without SDS. Additionally, SDS and reducing agents were eliminated from the running and sample loading buffers.

Statistics

Data were graphed as mean ± SEM. The differences between treatment means were tested using an ANOVA. Pairwise t-tests were performed to determine which means were different when the ANOVA was statistically significant. A mixed model was used to model blood glucose. Time, as a categorical variable, treatment, and time by treatment interaction were included in the model. T-tests were performed at each time point on the least square means from the model to determine if there were any statistically significant differences between the treatments. All tests used p < 0.05 as the level of statistical significance.

Results

Artemisia extracts act as PPARγ agonists and promote adipogenesis of 3T3-L1 cells

We screened over 400 botanical extracts for their ability to activate PPARγ and modulate adipogenesis in 3T3-L1 cells. Our results identified SCO and SAN as modulators of adipocyte development. As shown in Figure 1A, SCO and SAN increased ORO staining of 3T3-L1 cells during adipogenesis relative to the vehicle control. Artemisia rutifolia and GOP (grains of paradise) were not capable of promoting lipid accumulation relative to the vehicle control. We also examined the ability of these botanical extracts to modulate the expression of STAT5A and other adipocyte marker proteins, such as PPARγ and ADPN, which are induced during fat cell differentiation. SCO and SAN substantially increased the expression levels of the adipogenic marker proteins in 3T3-L1 adipocytes (Figure 1B). Consistent with ORO results, addition of A. rutifolia did not increase PPARγ, adiponectin, or STAT5A levels. Thus, SCO and SAN were selected for further investigation.

PPARγ belongs to the large nuclear receptor (NR) superfamily. We examined the ability of SCO and SAN to modulate the activity of all forty-eight known human NRs by utilizing a NR specificity assay. As previously demonstrated [11], activation and repression of NRs were denoted as increases or decreases (greater than 3 standard deviations), respectively, in fold change versus DMSO vehicle. SCO repressed and SAN stimulated the transactivating activity of the many of the NR ligand binding domains (LBDs), but these marginal modulations were not significant. However, SCO and SAN were capable of significantly stimulating PPARγ. As shown in Figure 2, both SCO and SAN significantly activated the LBD of PPARγ greater than 2 fold, and thus were extremely selective PPARγ agonists.

Physical and metabolic parameters of HFD-fed C57BL/6 mice treated with SCO and SAN

To investigate the ability of SCO and SAN to modulate adipocyte function in vivo, we used the DIO C57BL/6J mouse model. SCO and SAN (500 mg/kg) were administered to male mice daily via gavage for a period of two weeks. No significant effects on body weight, physical appearance and activity were observed as a result of pre-treatment with Labrasol® for one week. There were no significant differences in fasting body weight, fat mass (FM), fat free mass (FFM), or the ratio of fat mass to lean mass (FM/LM) between the CTL and
SCO or SAN-treated mice at the end of the two-week treatment (data not shown). However, as shown in Figure 3, SCO-treated mice displayed increased insulin-induced glucose disposal relative to control mice during an IPITT. Differences in the blood glucose levels of SCO and CTL mice were statistically significant at the 20 and 60 min time points. Mice treated with SAN also displayed slightly improved insulin-sensitive glucose disposal, especially at time points between 20 and 60 minutes.

**SCO and SAN increase insulin sensitivity in WAT in a depot specific manner**

Following two weeks of botanical treatment, the mice were fasted overnight, and then injected with saline or insulin 10 minutes prior to sacrifice. eWAT, rWAT, and iWAT were collected and analyzed for Akt S473 phosphorylation. As shown in Figure 4, saline-injected animals exhibited little to no AktpS(473) in any of the WAT depots. In response to insulin, SCO- and SAN-treated mice displayed improved insulin sensitivity in eWAT when compared to controls, as indicated by higher levels of AktpS(473). In rWAT and iWAT, AktpS(473) levels were similar among all groups. Total Akt protein levels were not altered by botanical treatment in any WAT depot.

**SCO and SAN promote a beneficial adipokine profile in DIO mice**

We also examined the effects of SCO and SAN on plasma ADPN levels. Plasma levels of high molecular weight (HMW) and total ADPN were similar in SAN-treated and control animals. SCO-treated mice exhibited elevated circulating levels of both total and HMW ADPN (Figure 5) relative to controls, but this difference was not statistically significant. We also examined MCP-1 protein levels in the WAT lysates. As shown in Figure 6, we observed significant decreases in MCP-1 protein expression in the rWAT of SCO- and SAN-treated mice relative to control animals. This trend was also observed in eWAT, but not in iWAT (data not shown).

**Discussion**

Alterations in adipocytes and/or adipose tissue can have profound effects on metabolic disease states. Improvements in adipocyte differentiation and adipocyte function represent viable interventions for metabolic disease states including T2DM. For these reasons, we examined the effects of a variety of botanical extracts on adipocyte development and function. In a blinded screening study, we observed that ethanolic extracts from two related Artemisia species, *Artemisia scoparia* and *Artemisia santolinifolia* can promote adipocyte development *in vitro*. Moreover, extracts from these *Artemisia* species specifically activated PPARγ, a transcription factor known to promote adipocyte development *in vitro* and *in vivo* [15, 16]. Gavage studies in DIO mice were consistent with our *in vitro* observations and indicated that SCO and SAN treated animals had reduced glucose levels following an insulin tolerance test. We also observed increase insulin sensitivity as measured by Akt phosphorylation in epididymal fat, but not other white fat depots. Adiponectin is a hormone associated with cardioprotection and insulin sensitivity in mice in man [17, 18] and we observed increases globular and high molecular weight adiponectin in mice treated with SCO and SAN. These observations are consistent with the results of the insulin tolerance test and examination of insulin action in adipose tissue. We predict the ability of SCO and
SAN to improve insulin action may be mediated by its ability to limit inflammation in adipose tissue as our studies revealed that both *Artemisia* species reduced the expression of MCP-1 in adipose tissue. Although other *Artemisia* species have been shown to have anti-diabetic [5–7, 19] and insulin-sensitizing [20–22] activities, this is the first demonstration that *Artemisia* SCO and SAN species can modulate adipocyte development and function. There is also evidence to suggest that *Artemisia scoparia* can attenuate lipid accumulation in liver and enhance hepatic insulin sensitivity [23]. Overall, our studies demonstrate that two related *Artemisia* species have a positive impact on adipocyte related diseases by enhancing differentiation of preadipocytes and increasing insulin sensitivity in adipose tissue *in vivo*.

**Acknowledgments**

We would like to thank Anik Boudreau for technical assistance, Dr. Carrie Elks for assistance with manuscript preparation, and Drs. William Johnson and Dr. Robbie Beyl for assistance with statistical analyses. Also, we gratefully acknowledge Dr. Randy Mynatt and Tamra Mendoza in the Integrative Biology Core of our Botanical Research Center for help with the gavage studies.

**Funding:**

NCAAM and ODS funded NIH grant-2P50AT002776-06. AJR was supported by an NIH T-32 postdoctoral training fellowship in botanicals granted to Pennington Biomedical Research Center (T32 AT004094).

**Abbreviations**

- **T2DM**: Type 2 Diabetes Mellitus
- **SCO**: *Artemisia scoparia* extracts
- **SAN**: *Artemisia santolinifolia* extracts
- **PPARγ**: peroxisome proliferator-activated receptor gamma
- **ADPN**: adiponectin
- **DMEM**: Dulbecco’s Modified Eagle’s Medium
- **STAT5A**: signal transducer and activator of transcription 5
- **MAPK**: mitogen-activated protein kinase
- **MCP-1**: monocyte chemoattractant protein-1
- **BCA**: bicinchoninic acid
- **DMSO**: dimethyl sulfoxide
- **FBS**: fetal bovine serum
- **MDI**: 1-methyl-3-isobutylxanthine, dexamethasone, and insulin
- **ORO**: Oil Red O
- **DIO**: diet induced obesity
- **HFD**: high fat diet
- **NMR**: nuclear magnetic resonance
- **IPITT**: intraperitoneal insulin tolerance test
inguinal, epididymal, and retroperitoneal white adipose tissue

sodium dodecyl sulfate

polyacrylamide

ANAnalysis Of VAriance between groups

Reference List


Nutrition. Author manuscript; available in PMC 2015 July 01.


Figure 1. SCO and SAN promote adipogenesis of 3T3-L1 cells
Differentiation of murine 3T3-L1 preadipocytes was induced using the standard induction cocktail containing 50µg/ml of the indicated extracts (Artemisia rutifolia; RUT and Grains of Paradise; GOP), untreated control (CTL), or DMSO vehicle (V). A) Cell monolayers were subjected to ORO staining one week after induction. B) Western blot analysis was performed on whole cell extracts (100 µg protein) prepared from cells that were harvested one week after induction. The results represent three independently performed experiments.
Figure 2. SCO and SAN specifically activate PPARγ
The ability of SCO and SAN to modulate the transactivation all 48 human NRs was assessed using a NR specificity assay. HEK293 cells were co-transfected with Gal4 DNA binding domain – NR fusions and luciferase reporter constructs. Extracts were tested at 50 µg/ml, and DMSO was used as a vehicle control. The luciferase activity of each construct was measured and normalized to the mock (vector alone), and then the fold change in signal compared with DMSO was calculated (n = 4). Data are means +/- SEM (n = 4). Horizontal
dashed lines represent +/- 3 S.D. of the luciferase activity measured following DMSO treatment.
Figure 3. SCO and SAN improve glucose disposal in response to an intraperitoneal insulin injection

Mice were gavaged with 20% Labrasol® (CTL) in the presence or absence of SCO or SAN daily for one week. Blood glucose levels were monitored at the indicated time points following a single insulin injection of insulin. Data are presented as mean +/− SEM (n = 12).

*p ≤0.03, SCO versus CTL and **p ≤0.01, SCO or SAN versus CTL.
Figure 4. SCO and SAN increase insulin-induced Akt phosphorylation in eWAT
Tissue extracts of eWAT, iWAT, and rWAT from CTL-, SCO- and SAN-treated mice were subjected to Western blot analysis (50–150 µg protein). There were 6 mice per condition and three animals per condition are shown. For each depot, the results for each antibody are from the same exposure of the same blot. Densitometric analyses are shown to the right of each blot; AktpS(473) band intensities were normalized by the respective total Akt band intensities prior to comparison against CTL. Data are means +/- SEM (n = 3).

*Nutrition.* Author manuscript; available in PMC 2015 July 01.
Figure 5. SCO increases the plasma levels of HMW and total ADPN in DIO mice
Serum HMW and total ADPN were separated by native PA gel electrophoresis (50 µg protein) and SDS-PAGE, respectively, for HMW and total protein content, and visualized by Western blot analysis. Densitometric analysis is shown below each blot; Data are means +/− SEM (n = 3).
Figure 6. SCO and SAN decrease MCP-1 levels in WAT
rWAT from CTL-, SCO-, and SAN-treated mice was subjected to Western blot analysis (100 µg total protein/lane). Densitometric analysis is shown below the blot; MCP-1 band intensities were normalized to the respective MAPK band intensities prior to comparison against CTL. Data are means +/− SEM (n = 3).